INSPIRE II UPPER AIRWAY STIMULATOR
Inspire Medical Systems · Decision date Oct 26, 2026
What did the FDA approve?
FDA supplement P130008/S144, dated 2026-10-26, records an approval for a minor software update to the Model 2740S SleepSync Programmer Application. The stated purpose is to address known software bugs, improve user experience, and perform code maintenance, including updates to software of unknown provenance (SOUP). The supplement type is Real-Time Process, and the reason is Change Design/Components/Specifications/Material.
This supplement does not represent a new approval of the INSPIRE II Upper Airway Stimulator system. The record identifies the device as a Stimulator, hypoglossal nerve, implanted, apnea under product code MNQ, with the applicant Inspire Medical Systems. The source statement reports the intended scope of the software change but does not provide independent proof of safety or clinical effectiveness for the updated programmer application.
FDA approval order statement
approval for a minor software update to the Model 2740S SleepSync Programmer Application to address known software bugs, improve user experience, and perform code maintenance which includes updates to software of unknown provenance (SOUP).
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Oct 26, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P130008/S144
- Regulatory pathway
- PMA supplement
- Applicant
- Inspire Medical Systems
- Product code
- MNQ
- Decision code
- APPR
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.
- Applicant
- Inspire Medical Systems
- Product code
- MNQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P130008. Subsequent supplements may change the device or its indications.
FDA decision timeline
P130008 · Original PMA
INSPIRE II UPPER AIRWAY STIMULATOR
P130008/S144 received
Application receipt date recorded by FDA.
P130008/S146 · Related supplement
Model 3150 IPG
P130008/S147 · Related supplement
Model 3150 IPG
P130008/S144 · FDA decision
Real-Time Process
P130008/S148 · Related supplement
Model 4063 Dedicated Tray Sealer
Timeline entries are records held by MedtechLedger for P130008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Inspire Medical Systems | PMA approval | Apr 30, 2014 | FDA | |
Model 3150 IPGP130008/S146 | Inspire Medical Systems | PMA supplement | Oct 13, 2026 | FDA |
Model 3150 IPGP130008/S147 | Inspire Medical Systems | PMA supplement | Oct 22, 2026 | FDA |
Model 4063 Dedicated Tray SealerP130008/S148 | Inspire Medical Systems | PMA supplement | Nov 5, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Inspire Medical Systems
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9700 63rd Ave. N., Suite 200, Maple Grove, MN, 55369
Sources and methodology
- Original FDA record: P130008/S144
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


